Published in Obesity and Diabetes Week, July 16th, 2007
Rimonabant is a first class therapy, discovered and developed by sanofi-aventis, Rimonabant is currently approved in 42 countries and marketed in 20 to treat obesity and overweight patients with associated cardiovascular risk factors.
New effective treatment options are needed for obesity, a growing public...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.